Michael H Mathews

US Patent:

8603814, Dec 10, 2013

Filed:

Jul 20, 2010

Appl. No.:

12/840270

Inventors:

Michael B. Mathews - Montclair NJ, US
Mainul Hogue - North Arlington NJ, US

Assignee:

Rutgers the State University of New Jersey - New Brunswick NJ

International Classification:

A61K 31/44
A61K 31/426
A61P 25/28
C12Q 1/68

US Classification:

4353723, 536 235, 514185, 514348

Abstract:

Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD a composition comprising an eIF5A inhibitor compound in an amount effective to prevent intracellular hypusination of eIF5A, whereby gene expression of NMD-susceptible mRNA is increased.

US Patent:

8630894, Jan 14, 2014

Filed:

Aug 12, 2011

Appl. No.:

13/208725

Inventors:

Leroy Robinson - Maplewood NJ, US
Cynthia Myricks - Massillon OH, US
Michael E. Mathews - Canton OH, US

International Classification:

G06F 11/00

US Classification:

705 12, 235386

Abstract:

System and method may control transmission of a notification to an assessor when a geographic designation set as criteria matches a geographic designation of the assessor. The notification may cause display, on a device of the assessor, of indicia indicating receipt of the notification in association with an icon representative of an integrated application of the device, and of information indicating a selected content item is available for assessment when the integrated application is selected. Monitoring information for the selected content item and the assessor may be updated, based on assessment information transmitted from the device using the integrated application.

US Patent:

20120095058, Apr 19, 2012

Filed:

Dec 1, 2004

Appl. No.:

10/581658

Inventors:

Paul Palumbo - Westfield NJ, US
Myung-Hee Park - Potomac MD, US
Edith Wolff - Bethesda MD, US
Axel-Rainer Hanauske - Frankfurt, DE
Michael B. Mathews - Montclair NJ, US
Deepti Saxena - South Orange NJ, US
Mainul Hoque - Newark NJ, US

International Classification:

A61K 31/4418
A61K 31/4439
A61K 31/4412
A61P 31/18
A61P 31/14
C12N 5/071
A61K 31/426
A61P 31/12

US Classification:

514342, 514345, 514365, 435375, 514348

Abstract:

The present invention discloses compounds and pharmaceutical compositions which are highly effective at inhibiting the accumulation of spliced and unspliced viral transcripts and their utilization for viral protein synthesis at cellular ribosomes, and at inhibiting the formation of the hypusine residue in cellular eIF-5A precursor proteins, the cellular cofactors that render spliced and unspliced viral transcripts translatable at the ribosomes of infectled cells. The invention further relates to methods of using such compounds and pharmaceutical compositions therefrom for inhibiting or preventing viral protein synthesis. Such inhibition cause a dose-dependent release from the virally induced arrest of the otherwise genetically preprogrammed apoptosis of virally infected cells, and in consequence, triggers their apoptotic ablation and the eradication of the chronic infection-mediating provirus integrated into their genome.

US Patent:

20120225093, Sep 6, 2012

Filed:

Oct 11, 2011

Appl. No.:

13/271190

Inventors:

Michael B. Mathews - Montclair NJ, US
Mainul Hoque - North Arlington NJ, US
Paul Palumbo - Lebanon NH, US
Deepti Saxena - South Orange NJ, US
Myung-Hee Park - Potomac MD, US

Assignee:

UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY - Somerset NJ

International Classification:

A61K 31/4412
A61K 31/4418
A61P 37/04
C40B 30/04
A61P 31/18
C12Q 1/70
A61K 39/21

US Classification:

4242081, 435 5, 514345, 514348, 506 9

Abstract:

The present invention relates to compositions and methods of treating, inhibiting, or controlling HIV infection.

US Patent:

20140073685, Mar 13, 2014

Filed:

Nov 18, 2013

Appl. No.:

14/082346

Inventors:

Michael B. Mathews - Montclair NJ, US
Mainul Hoque - North Arlington NJ, US

Assignee:

Rutgers, The State University of New Jersey - New Brunswick NJ

International Classification:

A61K 31/713
A61K 31/4412
A61K 31/4418

US Classification:

514 44 A, 514345, 514348

Abstract:

Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD a composition comprising an eIF5A inhibitor compound in an amount effective to prevent intracellular hypusination of eIF5A, whereby gene expression of NMD-susceptible mRNA is increased.

US Patent:

20170319612, Nov 9, 2017

Filed:

Jun 13, 2012

Appl. No.:

14/126342

Inventors:

Michael B. Mathews - Montclair NJ, US
Mainul Hoque - North Arlington NJ, US

Assignee:

RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY - New Brunswick NJ

International Classification:

A61K 31/7105
A61K 31/4418
A61K 31/7036
A61K 31/7048
A61K 31/4412
A61K 31/5025
A61K 45/06
A61K 31/7064
A61K 31/4375
A61K 31/502

Abstract:

Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD an inhibitor of NMD and a nonsense suppressor, whereby degradation of NMD susceptible mRNA is decreased and translation termination at a misplaced nonsense codon is blocked.

US Patent:

20160199361, Jul 14, 2016

Filed:

Aug 19, 2014

Appl. No.:

14/913169

Inventors:

- New Brunswick NJ, US
Paul Palumbo - Westfield NJ, US
Bernadette M. Cracchiolo - Edgewater NJ, US
Axel R. Hanauske - Hamburg, DE
Michael B. Mathews - Montclair NJ, US

International Classification:

A61K 31/4412
A61K 31/4418

Abstract:

A method of inducing an anti-retroviral immune response by counter-acting retro-virus induced anti-apoptosis is disclosed. The present invention relates, at least in part, to agents and methods for treating, inhibiting, vaccinating or controlling HIV. In certain non-limiting aspects, it relates to the reduction of viral load in an HIV-1 infected subject, while simultaneously developing immunological responsiveness within the subject toward HIV-1 that continues after the agent is removed or excreted from the subject's body.